NEW YORK, Aug 13 (Reuters) - A Boston Scientific Corp (BSX.N: Quote, Profile, Research, Stock Buzz) heart stent awaiting U.S. approval is backed by flawed research despite the medical device maker’s claims of success in a clinical study, the Wall Street Journal said in its online edition, citing the newspaper’s own review of the study data.
